Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Takebayashi, Ryusuke ^a   Izuishi, Kunihiko ^a,b   Yamamoto, Yuka ^a   Kameyama, Reiko ^a   Mori, Hirohito ^a   Masaki, Tsutomu ^a   Suzuki, Yasuyuki ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b Takamatsu Hospital   (Japan)

Author keywords

18 Fluorodeoxyglucose; Gastric cancer; Glucose transporter 1; Hypoxia inducible factor 1 ; Positron emission tomography

Indexed keywords

CYCLINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; GLUCOSE; GLUCOSE 6 PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SIZE; CORRELATION ANALYSIS; DRUG ACCUMULATION; DRUG UPTAKE; FEMALE; GASTRECTOMY; GLUCOSE TRANSPORT; HISTOPATHOLOGY; HUMAN; HYPOXIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; STOMACH CANCER; STOMACH MUCOSA; ANOXIA; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; STOMACH TUMOR; TRANSPORT AT THE CELLULAR LEVEL; TUMOR VOLUME; DIAGNOSTIC USE;

AGED; ANOXIA; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE-6-PHOSPHATASE; HEXOKINASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROLIFERATING CELL NUCLEAR ANTIGEN; RETROSPECTIVE STUDIES; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR BURDEN;

EID: 84878223263     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-34     Document Type: Article

References (33)

1. Japanese gastric cancer association task force for research promotion: clinical utility of §ssup§18§esup§F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Shimada H, Okazumi S, Koyama M, Murakami K, Gastric Cancer 2011 14 13 21 10.1007/s10120-011-0017-5 21331531
2. FDG-PET for Hepatobiliary and pancreatic cancer: advances and current limitations. Murakami K, World J Clin Oncol 2011 2 229 236 21611100
3. Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Alakus H, Batur M, Schmidt M, Drebber U, Baldus SE, Vallböhmer D, Prenzel KL, Metzger R, Bollschweiler E, Hölscher AH, Mönig SP, Nucl Med Commun 2010 31 532 538 20220543
4. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, Noh SH, Cancer 2005 103 2383 2390 10.1002/cncr.21074 15856477 (Pubitemid 40686585)
5. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K, World J Surg 2004 28 247 253 10.1007/s00268-003-7191-5 14961197 (Pubitemid 38375523)
6. Role of gastric distention with additional water in differentiating locally advanced gastric carcinomas from physiological uptake in the stomach on 18F-fluoro-2-deoxy-D-glucose PET. Kamimura K, Nagamachi S, Wakamatsu H, Fujita S, Nishii R, Umemura Y, Ogita M, Komada N, Sakurai T, Inoue T, Fujimoto T, Nakajo M, Nucl Med Commun 2009 30 431 439 10.1097/MNM.0b013e3283299a2f 19352209
7. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M, Ann Nucl Med 2006 20 597 604 10.1007/BF02984657 17294670 (Pubitemid 44954052)
8. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, Honma K, Suzuki T, Cancer 2001 92 634 641 10.1002/1097-0142(20010801)92:3<634::AID- CNCR1364>3.0.CO;2-X 11505409 (Pubitemid 32735200)
9. The value of PET imaging in patients with localized gastroesophageal cancer. Ott K, Herrmann K, Krause BJ, Lordick F, Gastrointest Cancer Res 2008 2 287 294 19259277
10. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ, Clin Cancer Res 2008 14 2012 2018 10.1158/1078-0432.CCR-07-0934 18381939 (Pubitemid 351551110)
11. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, Lordick F, Link T, Schwaiger M, Siewert JR, Weber WA, J Clin Oncol 2003 21 4604 4610 10.1200/JCO.2003.06.574 14673049 (Pubitemid 46594034)
12. Noninvasive grading of musculoskeletal tumors using PET. Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, al-Kaisi N, Miraldi F, J Nucl Med 1991 32 1508 1512 1869970
13. GLUT1 expression in tissue and (18)F-FDG uptake. Avril N, J Nucl Med 2004 45 930 932 15181126 (Pubitemid 47611678)
14. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Vander Heiden MG, Cantley LC, Thompson CB, Science 2009 324 1029 1033 10.1126/science.1160809 19460998
15. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Paudyal B, Oriuchi N, Paudyal P, Tsushima Y, Higuchi T, Miyakubo M, Ishikita T, Nakajima T, Endo K, Ann Nucl Med 2008 22 83 86 10.1007/s12149-007-0076-1 18250992 (Pubitemid 351207655)
16. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, Di Bisceglie AM, J Hepatol 2000 32 792 797 10845666 (Pubitemid 30262739)
17. Diagnosis of maxillofacial tumor with L-3-[18F]-fluoro-alpha- methyltyrosine (FMT) PET: a comparative study with FDG-PET. Miyakubo M, Oriuchi N, Tsushima Y, Higuchi T, Koyama K, Arai K, Paudyal B, Iida Y, Hanaoka H, Ishikita T, Nakasone Y, Negishi A, Mogi K, Endo K, Ann Nucl Med 2007 21 129 135 10.1007/BF03033991 17424980 (Pubitemid 46495613)
18. Growth regulation of the PCNA gene. Baserga R, J Cell Sci 1991 98 433 436 1677646
19. HIF-1alpha: a valid therapeutic target for tumor therapy. Hong SS, Lee H, Kim KW, Cancer Res Treat 2004 36 343 353 10.4143/crt.2004.36.6.343 20368827
20. Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D: -glucose positron emission tomography. Izuishi K, Yamamoto Y, Sano T, Takebayashi R, Nishiyama Y, Mori H, Masaki T, Morishita A, Suzuki Y, J Gastrointest Surg 2012 16 394 400 10.1007/s11605-011-1727-z 22065316
21. Correlation of 18F-FLT uptake with equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in gastrointestinal cancer. Kameyama R, Yamamoto Y, Izuishi K, Sano T, Nishiyama Y, Nucl Med Commun 2011 32 460 465 10.1097/MNM.0b013e32834209b5 21423062
22. Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma. Kuang Y, Schomisch SJ, Chandramouli V, Lee Z, Comp Biochem Physiol C Toxicol Pharmacol. 2006 143 225 231 10.1016/j.cbpc.2006.02.005 16581304
23. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Di Fabio F, Pinto C, Rojas Llimpe FL, Fanti S, Castellucci P, Longobardi C, Mutri V, Funaioli C, Sperandi F, Giaquinta S, Martoni AA, Gastric Cancer 2007 10 221 227 10.1007/s10120-007-0438-3 18095077 (Pubitemid 350308171)
24. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T, Int J Clin Oncol 2010 15 588 593 10.1007/s10147-010- 0120-3 20809217
25. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. Izuishi K, Yamamoto Y, Sano T, Takebayashi R, Masaki T, Suzuki Y, J Gastrointest Surg 2010 14 1151 1158 10.1007/s11605-010- 1207-x 20443074
26. Correlation between glucose transporter-1 expression and 18F-fluoro-2-deoxyglucose uptake on positron emission tomography in lung cancer. Usuda K, Sagawa M, Aikawa H, Ueno M, Tanaka M, Machida Y, Zhao XT, Ueda Y, Higashi K, Sakuma T, Gen Thorac Cardiovasc Surg 2010 58 405 410 10.1007/s11748-010-0603-1 20703861
27. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG, Ann Thorac Surg 1995 60 1348 1352 10.1016/0003-4975(95)00754-9 8526625
28. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II. Ong LC, Jin Y, Song IC, Yu S, Zhang K, Chow PK, Acta Radiol 2008 49 1145 1153 10.1080/02841850802482486 18979289
29. Oncogenic alterations of metabolism. Dang CV, Semenza GL, Trends Biochem Sci 1999 24 68 72 10.1016/S0968-0004(98)01344-9 10098401 (Pubitemid 29346576)
30. Targeting HIF-1 for cancer therapy. Semenza GL, Nat Rev Cancer 2003 3 721 732 13130303 (Pubitemid 37328811)
31. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. Berger KL, Nicholson SA, Dehdashti F, Siegel BA, AJR Am J Roentgenol 2000 174 1005 1008 10.2214/ajr.174.4.1741005 10749239 (Pubitemid 30179992)
32. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, Esumi H, Soga T, Cancer Res 2009 69 4918 4925 10.1158/0008-5472.CAN-08-4806 19458066
33. Role of glutamine in cancer: therapeutic and imaging implications. Rajagopalan KN, DeBerardinis RJ, J Nucl Med 2011 52 1005 1008 10.2967/jnumed.110.084244 21680688